The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog
…
Category: Federal
“Pharma Bro” Martin Shkreli’s former company and former business partner agreed Tuesday to settle legal claims brought against them by the U.S. and seven state governments arising from the company’s purchase of and 4,000% price increase on the drug Daraprim,
…
The University of Kansas Medical Center (KUMC) has filed suit challenging the continuation in 2021 of a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B-purchased physician-administered drugs.
KUMC filed the suit Nov. 24 in U.S. District Court
…
Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,”
…
The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.
The Dec. 9 hearing starts at 10:30 a.m. Eastern. It’s
…
The federal government on Wednesday told the judge that ruled against it in drug makers Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits it needs more “time to decide whether to file appeals.”
The government’s Dec. 1 statement about
…
Precision Dose, a maker of liquid generic drugs in unit-dose syringes and cups, and Tagi Pharma, a wholly owned subsidiary that makes generic oral and injectable drugs, will have to repay 340B covered entities for overcharges following an 340B program
…
Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.
Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior
…
340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.
On Monday, the justices heard the case of
…
Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in
…